ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!VKTX Company Profile and Key Details
Viking Therapeutics, Inc.
VKTX Stock Price Chart
Stock Price Today
Viking Therapeutics, Inc. (VKTX) stock declined over -14.29%, trading at $29.20 on NASDAQ, down from the previous close of $34.07. The stock opened at $33.90, fluctuating between $29.02 and $34.03 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Company Information
| Employees | 30 |
| Beta | 0.89 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Viking Therapeutics, Inc. (NASDAQ: VKTX) stock price is $29.20 in the last trading session. During the trading session, VKTX stock reached the peak price of $34.03 while $29.02 was the lowest point it dropped to. The percentage change in VKTX stock occurred in the recent session was -14.29% while the dollar amount for the price change in VKTX stock was -$4.87.
The NASDAQ listed VKTX is part of Biotechnology industry that operates in the broader Healthcare sector. Viking Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Michael Morneau
Vice President of Fin. & Admin.
Dr. Brian Lian Ph.D.
Pres, Chief Executive Officer & Director
Mr. Gregory S. Zante
Chief Financial Officer
Ms. Marianne Mancini
Chief Operating Officer
Dr. Geoffrey E. Barker Ph.D.
Senior Vice President of Pharmaceutical Devel.
VKTX's closing price is 1.96% higher than its 52-week low of $28.64 where as its distance from 52-week high of $99.41 is -70.63%.
Number of VKTX employees currently stands at 30.
Official Website of VKTX is: https://www.vikingtherapeutics.com
VKTX could be contacted at phone 858 704 4660 and can also be accessed through its website. VKTX operates from 9920 Pacific Heights Boulevard, San Diego, CA 92121, United States.
VKTX stock volume for the day was 8.84M shares. The average number of VKTX shares traded daily for last 3 months was 4.07M.
The market value of VKTX currently stands at $3.25B with its latest stock price at $29.20 and 111.44M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com